Clin Infect Dis by Bradley, Heather et al.
Ryan White HIV/AIDS Program Assistance and HIV Treatment 
Outcomes
Heather Bradley1, Abigail H. Viall1, Pascale M. Wortley1, Antigone Dempsey2, Heather 
Hauck2, and Jacek Skarbinski1
1Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 
2HIV/AIDS Bureau, Health Resources and Services Administration, Rockville, Maryland
Abstract
Background—The Ryan White HIV/AIDS Program (RWHAP) provides persons infected with 
human immunodeficiency virus (HIV) with services not covered by other healthcare payer types. 
Limited data exist to inform policy decisions about the most appropriate role for RWHAP under 
the Patient Protection and Affordable Care Act (ACA).
Methods—We assessed associations between RWHAP assistance and antiretroviral therapy 
(ART) prescription and viral suppression. We used data from the Medical Monitoring Project, a 
surveillance system assessing characteristics of HIV-infected adults receiving medical care in the 
United States. Interview and medical record data were collected in 2009–2013 from 18 095 
patients.
Results—Nearly 41% of patients had RWHAP assistance; 15% relied solely on RWHAP 
assistance for HIV care. Overall, 91% were prescribed ART, and 75% were virally suppressed. 
Uninsured patients receiving RWHAP assistance were significantly more likely to be prescribed 
ART (52% vs 94%; P < .01) and virally suppressed (39% vs 77%; P < .01) than uninsured patients 
without RWHAP assistance. Patients with private insurance and Medicaid were 6% and 7% less 
likely, respectively, to be prescribed ART than those with RWHAP only (P < .01). Those with 
private insurance and Medicaid were 5% and 12% less likely, respectively, to be virally suppressed 
(P ≤ .02) than those with RWHAP only. Patients whose private or Medicaid coverage was 
supplemented by RWHAP were more likely to be prescribed ART and virally suppressed than 
those without RWHAP supplementation (P ≤ .01).
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Conclusions—Uninsured and underinsured HIV-infected persons receiving RWHAP assistance 
were more likely to be prescribed ART and virally suppressed than those with other types of 
healthcare coverage.
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Human immunodeficiency virus (HIV) causes a chronic infection, which without treatment 
leads to AIDS, substantial morbidity, and premature death. Treatment of HIV infection with 
antiretroviral therapy (ART) to achieve viral suppression reduces morbidity, mortality, and 
risk of HIV transmission [1, 2]. For 25 years, the Ryan White HIV/AIDS Program 
(RWHAP) has been the payer of last resort for uninsured and underinsured HIV-infected 
persons in the United States, providing outpatient medical care, medications, and supportive 
services that are otherwise inaccessible to these individuals [3].
RWHAP provides assistance with HIV medical care through several mechanisms. RWHAP 
provides funding for medical services directly to HIV care facilities, and previous research 
suggests these facilities perform favorably to other facilities providing HIV medical care [4–
8]. RWHAP also provides assistance with HIV medical care for persons who are uninsured 
or have incomplete coverage for HIV-related medications and services [9], but less is known 
about the impact of this assistance. Grants may be used to pay individuals’ insurance 
premiums or deductibles for other types of healthcare coverage or to provide nonmedical 
supportive services (eg, case management, adherence support, transportation assistance, etc.) 
to HIV-infected persons.
Under the Patient Protection and Affordable Care Act (ACA), many HIV-infected persons 
are eligible for Medicaid coverage or private insurance through health insurance 
marketplaces [10]. Questions remain about the most appropriate role for RWHAP given 
expanded options for healthcare coverage [11, 12]. Thus, a better understanding of HIV 
treatment outcomes among persons with and without RWHAP assistance is needed. Using 
data from the Medical Monitoring Project (MMP), a nationally representative sample of 
HIV-infected adults receiving medical care, we assessed the association between RWHAP 
assistance, alone and in combination with other sources of healthcare coverage, and 
prescription of ART and viral suppression.
METHODS
MMP is a surveillance system designed to produce nationally representative, cross-sectional 
estimates of behavioral and clinical characteristics of HIV-infected adults receiving medical 
care in the United States [13]. MMP utilizes a 3-stage, complex sampling design in which 
US states and territories are sampled, followed by facilities providing outpatient HIV 
medical care in those jurisdictions, then HIV-infected adults (aged 18 years and older) 
receiving care in those facilities. We used MMP data collected from adults with at least 1 
HIV medical care visit to participating facilities during January to April of each of 4 years: 
2009, 2010, 2011, and 2012. Data were collected from June 2009 through May 2013 using 
face-to-face patient interviews and medical record abstractions.
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All sampled states and territories participated in MMP. Facility response rates ranged from 
76% to 85% from 2009 to 2012. Approximately 50% of persons sampled from these 
facilities completed an interview and had their medical records abstracted. Data were 
weighted to account for unequal probabilities of selection and both facility and patient 
nonresponse. Characteristics of nonresponding facilities and patients were available through 
program and surveillance data. These data were used to weight MMP data based on 
predictors of nonresponse.
In accordance with the federal human subjects protection regulations at 45 Code of Federal 
Regulations 46.101c and 46.102d [14] and with the Guidelines for Defining Public Health 
Research and Public Health Non-Research [15], MMP was determined to be a nonresearch, 
public health surveillance activity used for disease control program or policy purposes. As 
such, MMP is not subject to federal investigational review board review. Participating states 
or territories and facilities obtained local institutional review board approval to conduct 
MMP if required locally. Informed consent was obtained from all interviewed participants.
We examined the association between RWHAP assistance and 2 analytic outcomes 
measured using information from participants’ medical records: prescription of ART, 
defined as having a documented ART prescription during the 12 months prior to interview, 
and viral suppression, defined as having a suppressed HIV viral load (undetectable or <200 
copies/mL) at last measurement. The independent variable of interest, healthcare payer type, 
includes RWHAP assistance as well as other sources of healthcare coverage. Payer type was 
ascertained through interviews, in which participants were asked about type(s) of health 
insurance or coverage they had and sources of financial assistance for ART. Participants 
could list multiple types of healthcare coverage and/or sources of financial support for ART, 
and they could list payer types either by name or generically. For example, patients could 
name a payer type as either Medicaid or their state’s local Medicaid program (ie, Medi-Cal 
in California). Responses were recoded accordingly for all payer types, including RWHAP, 
and then combined into a single indicator that accounts for all major, observed combinations 
of payer types.
We conducted 3 comparisons with regard to ART and viral suppression: (1) patients with 
RWHAP only compared to uninsured patients not receiving RWHAP assistance, (2) patients 
with RWHAP only compared to patients with other source(s) of healthcare coverage, and (3) 
patients with healthcare coverage supplemented by RWHAP assistance compared to patients 
with other healthcare coverage alone.
First, we estimated the percentage of patients with each payer type and compared patients by 
payer type by other characteristics, ART prescription, and viral suppression. We used the 
following simplified categories for payer type: RWHAP assistance only; other healthcare 
coverage only; other healthcare coverage + RWHAP assistance; and uninsured, not receiving 
RWHAP assistance. We also compared patients by the aforementioned, more detailed payer 
categories (Supplementary Table 1). Patient characteristics included descriptors elicited by 
interview (gender, age, race/ethnicity, nativity, education level, poverty status, homelessness 
status, and time since HIV diagnosis) and by medical record abstraction (HIV disease stage). 
We categorized stage of HIV disease as stage 1 (no AIDS and nadir CD4 + T-lymphocyte 
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cell (CD4) count ≥500 cells/mm3), stage 2 (no AIDS and nadir CD4 count 200–499 
cells/mm3), or stage 3 (AIDS or nadir CD4 count <200 cells/mm3) [16]. Nadir CD4 count 
was defined as the lowest CD4 cell count measured after HIV diagnosis.
Next, we separately estimated the proportion of patients prescribed ART and who were 
virally suppressed by patient characteristics including payer type. Global F-tests were used 
to test for statistical significance of the associations between patient characteristics, 
including payer type, and each outcome.
Using participants with RWHAP only as a reference group, we estimated unadjusted and 
adjusted prevalence ratios by payer type for the 2 outcomes. To estimate adjusted prevalence 
ratios, we first constructed a multivariate logistic regression model for each outcome. 
Potential confounders that were associated with payer type and the outcome in question at P 
≤ .10 were added to the model using forward stepwise selection. We used this model to 
estimate average marginal predictions, or the average of predicted probabilities across a 
group (eg, 18–29 year-olds), accounting for the distribution of other covariates in that group. 
Adjusted prevalence ratios were then estimated by calculating the ratio of one predicted 
probability to another. We combined the ‘other public,’ ‘other public + RWHAP,’ and ‘VA/
CHAMPUS/Tricare’ categories with the ‘other’ category, because the sizes of these groups 
were too small for multivariate analysis.
Finally, for each outcome, we examined associations between having healthcare coverage 
(private, Medicaid, Medicare, Medicare + Medicaid) supplemented by RWHAP assistance 
to having the same type of healthcare coverage alone. We used results from the multivariate 
models to compare the adjusted predicted probability of either being prescribed ART or 
being virally suppressed with healthcare coverage supplemented by RWHAP assistance vs 
the same type of healthcare coverage alone.
We accounted for the complex survey design in all analyses, estimating standard errors of 
the estimates using Taylor linearization. All percentages represent weighted percentages. 
Stata 12 was used for all analyses (StataCorp. 2011. Stata Statistical Software: Release 12. 
College Station, Texas).
FINDINGS
Of the 18 095 participants, 46 (0.3%) were missing data for payer type, resulting in an 
analytic sample of 18 049 (Table 1). In all, 40.7% of HIV-infected adults in medical care 
received RWHAP assistance, including15.3% who relied solely on RWHAP for HIV care 
and 25.4% who relied on RWHAP in combination with other healthcare coverage. Nearly 
57% of patients had other healthcare coverage only, including private insurance (17.0%), 
Medicaid (15.9%), Medicare (3.4%), or both (9.4%). Only 2.7% of patients were uninsured, 
not receiving RWHAP assistance.
Among HIV-infected adults in medical care, 72.4% were male, 76.4% were at least 40 years 
old, 41.3% were non-Hispanic black, 34.5% were non-Hispanic white, and 19.3% were 
Hispanic. Nearly 52.0% had more than a high school education, 44.2% lived at or below the 
federal poverty level [17, 18], and 8.2% had been homeless (McKinney-Vento definition of 
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homelessness: living on the street, living in a shelter, living in a single-room-occupancy 
hotel, temporarily staying with friends or family, or living in a car. A person is categorized 
as homeless if that person lacks a fixed, regular, adequate night-time residence or has a 
steady night-time residence that is 1) a supervised publicly or privately operated shelter 
designed to provide temporary living accommodation, 2) an institution that provides a 
temporary residence for persons intended to be institutionalized, or 3) a public or private 
place not designed for or ordinarily used as a regular sleeping accommodation for human 
beings [eg, in an automobile or under a bridge] [Stewart B. McKinney Homeless Assistance 
Act, 42 U.S.C. §11 301, et seq; 1987]) in the past 12 months. Over half (56.6%) had been 
diagnosed with HIV for at least 10 years, and 68.7% had ever had stage 3 disease. Overall, 
91.1% of patients were prescribed ART, and 74.7% were virally suppressed.
All patient characteristics varied significantly by payer type (P ≤ .01 for all characteristics). 
Uninsured patients with or without RWHAP assistance were younger and more likely to 
have household incomes at or below the federal poverty level, have been homeless during 
the past 12 months, and have been diagnosed with HIV for 5 years or fewer than patients 
with other types of coverage.
Patients with RWHAP Only Compared to Uninsured Patients not receiving RWHAP 
Assistance
Among patients with RWHAP only, 94.2% were prescribed ART, compared to 52.1% of 
those who were uninsured, not receiving RWHAP assistance (P < .01) (Table 1). Similarly, 
76.7% of patients with RWHAP only were virally suppressed, compared to 38.8% of those 
uninsured, not receiving RWHAP assistance (P < .01).
Patients with RWHAP Only Compared to Patients with Other Healthcare Coverage
To assess how payer type was associated with ART prescription and viral suppression, we 
excluded uninsured patients not receiving RWHAP assistance, resulting in an analytic 
sample of 17 560.
Among patients with some payer type for HIV medical care, payer type was associated with 
having been prescribed ART and viral suppression (Table 2). Of patients with RWHAP only, 
94.2% were prescribed ART, and 76.7% were virally suppressed. Patients with Medicare + 
RWHAP (96.3%) or Medicaid + Medicare + RWHAP (96.4%) were most likely to be 
prescribed ART, whereas those with private (88.5%), Medicaid (88.8%) or other public 
coverage (88.7%) were least likely. Patients with private + RWHAP (82.4%) or Medicare + 
RWHAP (82.2%) were most likely to be virally suppressed, and those with Medicaid 
(65.7%) or Medicaid + RWHAP (70.4%) were least likely. Prescription of ART and viral 
suppression were also associated with other patient characteristics.
After adjustment for patient characteristics, patients with private insurance, Medicaid, 
Medicare, or Medicaid + Medicare were 4%–7% less likely to be prescribed ART than those 
with RWHAP only (Table 3). Patients with Medicaid were 12% less likely to be virally 
suppressed than those with RWHAP only, whereas those with private insurance, Medicaid + 
Medicare, and Medicaid + RWHAP were 4%–5% less likely to be virally suppressed (Table 
4).
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Patients with Healthcare coverage Supplemented by RWHAP Assistance Compared to 
Patients with Other Healthcare coverage only
Patients whose private insurance or Medicaid coverage was supplemented by RWHAP 
assistance had better treatment outcomes than those without RWHAP supplementation. 
Those with private insurance + RWHAP were significantly more likely to be prescribed 
ART than those with private insurance only (96.0% vs 90.0%) (Figure 1). Those with 
Medicaid + RWHAP were more likely to be prescribed ART than those with Medicaid only 
(95.0% vs 89.0%). Patients with private insurance + RWHAP were significantly more likely 
to be virally suppressed than those with private insurance only (81.0% vs 76.0%), as were 
patients with Medicaid + RWHAP compared to those with Medicaid only (76.0% vs 71.0%).
DISCUSSION
RWHAP provides essential support for HIV care to uninsured and underinsured HIV-
infected persons. More than 40% of HIV-infected patients in medical care during 2009–2012 
relied on RWHAP, including 15% who relied solely on RWHAP for HIV medical care. 
Compared to the 3% of uninsured patients not receiving RWHAP assistance, uninsured 
persons whose HIV medical care was supported by RWHAP were nearly twice as likely to 
be prescribed ART and virally suppressed.
As a payer of last resort, RWHAP serves a sociodemographically disadvantaged population. 
As expected, we found that uninsured patients receiving RWHAP assistance were more 
likely to have incomes at or below the federal poverty level and to have been homeless 
during the past year than those with other types of coverage, and that these characteristics 
were negatively associated with viral suppression. Less expected was the finding that when 
sociodemographically disadvantaged patients received RWHAP assistance, they were more 
likely to be prescribed ART and virally suppressed than those with other types of coverage, 
including private insurance.
The largest observed differences in treatment outcomes were between patients receiving 
RWHAP assistance and those with Medicaid. Even patients with Medicaid + Medicare and 
Medicaid + RWHAP were less likely to be virally suppressed than those with RWHAP only. 
It should be noted that patients with Medicaid were more likely to have incomes at or below 
the federal poverty level than those with all other payer types, including the uninsured. We 
controlled for sociodemographic factors in our analysis but cannot rule out the possibility of 
residual confounding. Whereas the magnitude of this difference should be interpreted with 
caution, the significantly better treatment outcomes among patients with RWHAP only 
compared to those with Medicaid is an important finding.
Under the ACA, many HIV-infected persons are eligible for Medicaid coverage, and others 
are eligible to purchase private insurance through the marketplaces. However, increased 
eligibility for traditional sources of healthcare coverage is not a complete solution for 
uninsured and underinsured HIV-infected persons. First, some HIV-infected persons will 
remain uninsured if they reside in a state that is not expanding Medicaid [19], are not 
eligible for Medicaid due to residence in the United States <5 years, or are unable to afford 
private insurance. Second, these findings suggest that replacing HIV-infected persons’ 
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RWHAP assistance with private insurance or Medicaid alone may not be optimal in terms of 
treatment outcomes. Last, transitions from RWHAP assistance to other coverage types are 
likely to be complicated by variable drug formularies, levels of provider expertise, and cost-
sharing requirements, all of which could affect patient adherence and, ultimately, viral 
suppression [12]. RWHAP supplementation to private insurance or Medicaid may be one 
solution. Our analysis suggests that patients whose Medicaid or private insurance was 
supplemented by RWHAP were more likely to be prescribed ART and virally suppressed 
compared to those with Medicaid or private insurance only.
RWHAP’s impact on treatment outcomes is likely attributable to a number of pathways. 
These pathways include provision of medications, core medical and nonmedical case 
management, and supportive services such as substance abuse counseling, which are needed 
to promote ART treatment adherence, viral suppression, and overall health [9, 20, 21]. 
Importantly, RWHAP facilitates provision of these medical and supportive services using a 
coordinated approach similar to that of the medical home model, and many health providers 
in RWHAP facilities see HIV-infected patients exclusively [8, 12]. Patients with RWHAP 
only may have been more likely than those with other payer types, including those receiving 
supplemental RWHAP assistance, to receive coordinated care from RWHAP facilities 
serving as medical homes.
This study has limitations. First, we do not have information on which types of RWHAP 
support patients received; thus, we cannot attribute our findings to a particular service, or 
combinations of services, provided by RWHAP. RWHAP assistance was self-reported, and 
patients unaware of receiving RWHAP support may have underreported assistance. To 
alleviate this limitation, we asked patients to list all sources of health insurance or coverage 
either by name or generically, and we recoded state and local programs that received 
RWHAP funding as RWHAP assistance. Our data are cross-sectional, so we cannot establish 
temporality between RWHAP assistance and our outcomes. However, we know that 
RWHAP assistance was received during the same year that a participant was prescribed ART 
and virally suppressed based on medical record data. Last, RWHAP program data indicate 
that approximately 60% of HIV-diagnosed persons receive RWHAP assistance [22], which 
is higher than the 40% we observed. MMP represents HIV-diagnosed persons in HIV 
medical care during an index year and not all persons diagnosed with HIV, so these data 
sources cannot be directly compared.
Despite these limitations, we were able to examine the impact of RWHAP on HIV treatment 
outcomes through ascertainment of RWHAP and other healthcare coverage types and other 
patient characteristics. This is critical because payer type is highly associated with both 
sociodemographic characteristics and health status. For example, 73% of patients with 
Medicaid had ever had stage 3 HIV disease, compared to 56% of those with private 
insurance. By ascertaining key health status variables and associated sociodemographic 
variables, we were able to control for them in the multivariate analysis. The value of this 
analysis is perhaps best highlighted by the more extreme differences in viral suppression that 
we observed between RWHAP and other types of coverage after adjusting for other patient 
characteristics compared to those observed before adjustment.
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RWHAP is likely to remain an important source of support for HIV medical care, even as 
some HIV-infected persons’ coverage options increase under the ACA. HIV-infected persons 
have complex needs for both medical care and supportive services; transitioning this 
population to traditional sources of healthcare coverage may not be straightforward or 
optimal. Flexible and creative strategies may become more essential as RWHAP strives to 
maintain and further improve HIV care and treatment outcomes in an evolving healthcare 
environment.
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Adjusteda prevalence of (A) being prescribed antiretroviral therapy (ART) and (B) having 
human immunodeficiency virus (HIV) viral load <200 copies/mL, by private, Medicaid, or 
Medicare healthcare coverage and receipt of Ryan White HIV/AIDS Program (RWHAP) 
assistance among HIV-infected adults receiving medical care: Medical Monitoring Project, 
2009–2013. Prevalence estimates are predicted probabilities from logistic regression model 
adjusted for (a) age, race, time since HIV diagnosis, and HIV disease stage and (b) age, race, 
nativity, poverty, education level, homelessness, and HIV disease stage. *P ≤ .01 for χ2 test 
comparing healthcare coverage with and without RWHAP.
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